Is GlaxoSmithKline a Buy?
Over the past several years, British pharmaceutical giant GlaxoSmithKline (NYSE: GSK) has been struggling to compete against some of its peers in the big pharma space. Despite maintaining an impressive dividend for all these years, investors have started getting worried about Glaxo's mounting debt levels and its struggle to generate revenue between its various divisions. Amidst this uncertainty for the future, most analysts covering the stock currently have a neutral rating on the company, adopting a wait-and-see approach.
However, the past few months have seen a number of major changes and announcements that are highly promising. Let's take a look at some of these recent developments and see whether or not Glaxo might be worth buying now.
IMAGE SOURCE: GETTY IMAGES.
Source Fool.com
